Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Condition(s):Classical Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Refractory Hodgkin LymphomaLast Updated:September 14, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Classical Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Refractory Hodgkin LymphomaLast Updated:September 14, 2023Active, not recruiting
Condition(s):Breast Neoplasms; Malignant Neoplasm of BreastLast Updated:January 12, 2024Active, not recruiting
Condition(s):Mantle Cell LymphomaLast Updated:June 1, 2016Completed
Condition(s):Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic LeukemiaLast Updated:January 23, 2024Active, not recruiting
Condition(s):Metastatic Renal Cell Cancer; Stage IV Renal Cell CancerLast Updated:February 10, 2022Completed
Condition(s):Relapsed or Refractory Mantle Cell LymphomaLast Updated:November 7, 2018Approved for marketing
Condition(s):Waldenström’s MacroglobulinemiaLast Updated:June 9, 2023Completed
Condition(s):Recurrent Mantle Cell LymphomaLast Updated:February 5, 2024Active, not recruiting
Condition(s):B-cell Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Well-differentiated Lymphocytic Lymphoma; B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin’s Lymphoma; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; B-Cell Diffuse LymphomaLast Updated:May 27, 2020Completed
Condition(s):Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic LymphomaLast Updated:September 27, 2017Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.